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Abstract 
Mitochondrial creatine kinase (mtCK) activity has been measured in the mitochondria isolated from the muscle of 69 patients 
suspected of mitochondrial diseases. The isolated mitochondria did not contain significant amounts of the muscle isoform of creatine 
kinase, as checked by an irnmunoassay performed after electrophoretic separation of the various isoforms. Hence, the enzyme assay 
reliably represented the mtCK activity. Therefore, a simple measurement of CK activity in isolated mitochondria permitted the 
measurement of mtCK activity. An absence of mtCK activity in muscle was never observed. The lowest activities were not associated to
defined mitochondrial diseases linked to defects of respiratory chain complexes or to defects of citric cycle enzymes. On the contrary, 
mtCK activity was significantly increased in the muscle of patients exhibiting ragged red fibers. This increase was generally associated to
an increase of citrate synthase activity. Since ragged-red fibers and elevated mtCK activities were generally not found in children younger 
than 3 years, even in cases of characteristic oxidative phosphorylation deficiency, it is suggested that the increase in mtCK activity as well 
as the appearance of ragged-red fibers are not the first events which occur during the evolution of mitochondrial diseases but would rather 
be long-term secondary processes which slowly develop in deficient mitochondria. 
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1. Introduction 
Pathologies in which a mitochondrial defect is thought 
to be the primary cause of the disease are biochemically, 
genetically and clinically heterogeneous [1]. Biochemical 
analysis, currently performed on muscle biopsies, can re- 
veal deficiencies in the oxidation rate of various substrates 
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mainly due to either dehydrogenase d ficiencies or various 
oxidative phosphorylation defects. The genetic origin of 
these diseases is also variable and the same genetic modifi- 
cation can be associated with different clinical symptoms 
and enzyme defects. MtDNA deletions [2] have been ob- 
served in patients with PEt ,  KSS [3], Pearson's yndrome 
[4] or diabetes mellitus with deafness [5]. MtDNA muta- 
tion in position 3243 of the mtDNA sequence [6] at the 
level of one of the mitochondrial tRNA ~eu genes is associ- 
ated to MELAS [7], cardiomyopathy as well as diabetes- 
deafness yndrome [5]. Similarly, myoclonic epilepsy asso- 
ciated with RRF is caused by a point mutation in the 
mitochondrial tRNN ys gene [8]. A variety of other mtDNA 
mutations, depletion or duplications have been described 
[1]. In some cases, the mutation or the deletion of the 
mtDNA identified in muscle is the genetic cause invoked 
to explain the neuromuscular symptoms as well as other 
pathologies uch as diabetes, deafness, cecitis, liver-, pan- 
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creas- or kidney-impairment. In addition, the suspicion for 
a mitochondrial disorder is often suggested by the associa- 
tion of the above symptoms involving apparently unrelated 
organs (see Ref. [1] for review). 
An accumulation of enlarged and/or abnormal mito- 
chondria in skeletal muscle fibers is the morphological 
hallmark of mitochondrial encephalomyopathies [9]. This 
accumulation can be demonstrated by the occurrence of 
the so-called 'ragged red' fibers (RRF) revealed by the 
modified Gomori's trichrome stain [10], an increased suc- 
cinate dehydrogenase activity often associated to a loss of 
cytochrome oxidase activity [11]. By electron microscopy, 
crystal-like mitochondrial inclusions have been frequently 
observed in RRF [12]. Stadhouders et al. [13-15] have 
shown that these inclusions heavily react with specific 
antibodies against mtCK. They suggest hat mtCK repre- 
sents a major component of mitochondrial inclusions. 
However, the role of these crystal-like structures in rela- 
tion to the patient pathology is poorly understood. Is mtCK 
involved as the cause of the disease? Does the accumula- 
tion of mtCK in paracrystalline inclusions represents a
compensatory mechanism to the energy metabolism defi- 
ciency? In both cases, the demonstration f the presence of 
mtCK in the RRF crystal-like structures uggests that an 
increase in mtCK synthesis could be a specific feature of 
mitochondrial diseases. The comprehension f the mecha- 
nism by which mtCK synthesis is induced might be a clue 
to understanding mitochondrial myopathies and, hopefully, 
to finding a way to stop their evolution in patients. 
Another question is to know whether a defect in mtCK 
might be a cause of some heretofore unidentified mito- 
chondrial diseases. For this purpose, quantitative measure- 
ments of mtCK activity in muscle biopsies have previously 
been performed in patients presenting a decreased rate of 
pyruvate oxidation without pyruvate dehydrogenase d fi- 
ciency or respiratory chain defect [16,17]. MtCK activity 
was determined, using a specific antibody-induced inhibi- 
tion of mtCK. In 2 patients out of 6 who fulfilled the 
clinical criteria of PEt ,  the mtCK activity was enhanced. 
The muscle samples of these 2 patients were the only ones 
in which both RRF and crystal-like structures could be 
observed while RRF alone were present in one of the other 
biopsies. Four other patients with a localized respiratory 
chain defect showed a high-normal or an increased mtCK 
activity. On the contrary, 11 patients with an unexplained 
decrease of oxidative phosphorylation had a normal mtCK 
activity. The authors concluded that mtCK deficiency is 
not frequently the primary defect in patients with a distur- 
bance in mitochondrial energy production but that more 
patients hould be investigated to allow a definite conclu- 
sion to be made. 
In the present work, mtCK activity has been enzymati- 
cally determined in isolated mitochondria without use of a 
specific antibody. Sixty-nine patients uffering from either 
a demonstrated or a suspected mitochondrial disease have 
been studied. 
2. Materials and methods 
Patients and muscle biopsies. Muscle biopsies were 
obtained from the vastus lateralis by open surgery, under 
local (adults) or epidural (children) anesthesia. All biopsies 
were performed after informed consent of patients or of 
their parents. The 69 investigated patients (age range: 3 
months to 72 years) presented one or several symptoms 
suggesting a mitochondrial myopathy. This suspicion was 
based on the clinical and laboratory data which are sum- 
marized in Table 1. Prior to the biopsy, the functional 
impairment of energy metabolism was generally suspected 
from the increase of the cell redox status leading to an 
increase lactate content or to an increase of the lactate to 
pyruvate (L/P)  ratio in serum and sometimes in cere- 
brospinal fluid [ 18,19]. 
Histochemistry. A sample was immediately snap-frozen 
in isopentane cooled in liquid nitrogen for histochemistry. 
RRF were looked for with the modified Gomori' s trichrome 
stain [10]. Counting of RRF was performed on at least 500 
fibres using a semi-automatic computer-assisted Leica 
ASM 68-K processor. Staining for cytochrome oxidase 
[20] and succinate dehydrogenase [21] activities were per- 
formed as described. 
Mitochondria preparation and oxidative phosphoryla- 
tion analysis. Another muscle sample (0.3-0.8 g) was 
brought to the laboratory within half-an-hour after the 
biopsy, in an ice-cold transport buffer containing 150 mM 
KC1, 1 mM EDTA and 10 mM phosphate (K), pH 7.4, for 
mitochondria preparation. The muscle thoroughly washed 
in the ice-cold homogenization buffer A (70 mM sucrose, 
220 mM mannitol, 1 mM EDTA, 10 mM Hepes, adjusted 
to pH 7.4 with KOH and 0.5% fatty acid free bovine 
serum albumin) was carefully minced with scissors, and 
incubated for 5 min with 1 mg subtilisin (Boehringer) per 
g of muscle in 5 ml of buffer A. The suspension was 
diluted in 25 ml of buffer A and centrifuged at 15 000 × g 
for 5 min. The pellet was rinsed with buffer A, suspended 
in 30 ml of buffer A and homogenized by 3 up and down 
strokes at about 500 rpm in a motor driven glass-teflon 
Potter. The homogenate was centrifuged for 5 min at 
1000 × g. The pellet resuspended in 20 ml of buffer A was 
homogenized once again by 3 strokes at about 750 rpm 
and centrifuged as above. The supematant fluids were 
centrifuged at 14000 × g for 10 min. The pellets were 
resuspended in 1.8 ml of buffer A, homogenized and 
centrifuged at 2000 × g for 5 rain. The washed mito- 
chondria obtained by a final centrifugation of the super- 
natant fluids at 14000 x g for 10 min were homogenized 
in a minimal volume of buffer A. The rates of substrate 
oxidation were measured by oxypolarography and the res- 
piratory chain complex enzymatic activities by spectropho- 
tometry, as previously described [18,22]. Protein concen- 
tration was determined with the bicinchoninic acid assay 
(Pierce), according to the manufacturer protocol. Citrate 
synthase activity was determined according to Srere [23], 
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before  and after  add i t ion  o f  0 .1% Tr i ton X -100.  By  com-  
par ing  the citrate synthase  act iv i ty  o f  the f i rst  bomogenate  
to that o f  the mi tochondf ia ,  a mi tochondr ia l  y ie ld  o f  
40 _+ 7% (8 pat ients  younger  than 12 years  o ld)  and o f  
31 ± 6% (9 pat ients  o lder  than 18 years  o ld)  was  ca lcu-  
lated. E lec t ron  mic roscopy  was  per fo rmed by  thin sect ion-  
ing o f  e i ther  f i xed  musc le  or  mi tochondr ia l  pel let ,  as 
descr ibed  in Ref .  [24]. 
Creatine kinase. Creat ine  k inase act iv i ty was  measured  
wi th  a pH-s ta t  ma inta in ing  the pH at a constant  va lue o f  
8.8 by automat ic  pumping  o f  0.01 N NaOH.  The  react ion  
med ium conta ined  4 mM ATP ,  5 mM acetate (Mg) ,  40 
mM creat ine,  0.05 mM EDTA,  0.05 mM di th iothre i to l ,  50 
mM acetate (K)  and 2 /zg o f  o l igomyc in  to inhib i t  mi to -  
chondr ia l  ATPase  act iv i ty  [25]. The  presence  o f  var ious 
creat ine k inase i so forms in iso lated mi tochondr ia  was  ana- 
Table 1 
Clinical and biochemical features of the investigated patients 
A: Muscle biopsy with RRF 
No. Age; sex Major symptoms L /P  mtDNA OX phos defect Diagnosis% %RRF CS mtCK 
A 1 3; M 2, 8 + KG oxidation KGDH 6 2.00 1.72 
A2 4; M 2 II 4 2.10 3.24 
A3 11 ; F 7, 11, 13, 17 Deletion I Diab-Deaf 2 2.70 2.73 
A4 13; M 1, 4, 11, 18 + Deletion I, IV KSS 4 2.20 0.64 
A5 20; F 3, 7, 8 IV 3 3.17 3.24 
A6 27; M l, 12 + nt 3243 I, IV MELAS 21 2.74 2.66 
A7 31; F 1, 8, Mat I + nt 3243 I, IV MELAS 7 2.96 2.57 
A8 31; F 1, 8, 12 + Deletion All complexes KSS 26 2.80 1.77 
A9 32; M 1 + nt15615 III cyt b * 63 * 3.24 3.04 
AI0 35; M 1 + III, IV(?) 1 3.52 0.97 
A11 39; F 1, 4 + Deletion IV PEO 5 1.40 1.00 
A12 40; M 1 4 3.68 3.67 
A 13 41; M 3, 8, Mat I nt 3243 I MELAS 5 0.92 0.97 
A 14 42; F 1, 3 + Deletion II +lI I ,  IV PEO 11 2.70 2.65 
A15 42; M 9, 16, Mat I IV 1 1.70 1.10 
A16 42; M 9, 16, Mat I I, IV 2 1.35 2.47 
AI7 43; F 1, 4 1 2.10 3.90 
A18 54; F 3, 4 + Deletion I PEO 3 1.6 2.64 
AI9 54; M 1, 3 + I, IV 1 3.03 3.88 
A20 56; M 4, 19 I 3 2.30 2.19 
A21 64; F 3, l l ,  12, 19 V? IBM 1 1.60 1.70 
A22 64; M 3 + 2 1.40 1.10 
A23 72; F 3, 4 + I, IV 1 1.72 1.38 
B: Muscle biopsy with respiratory deficiencies but no RRF 
No. Age; sex Major symptoms L /P  mtDNA OX Phos defect Diagnosis CS mtCK 
B1 3m; F 5, 15 + V? 1.88 1.89 
B2 3m; M 2, 15 + All complexes 1.60 0.77 
B3 3m; M 2, 15 + Succinate 1.51 2.00 
B4 3m; M 12, 14 I 2.20 2.79 
B5 6m; M 2, 5 + I, IV Leigh (?) 1.67 1.40 
B6 6m; M Pancreas-marrow synd. I, IV 2.08 1.56 
B7 7m; M 2, 5 + I, II CMD 1.87 0.50 
B8 7m; M 7, 13, 17 + Deletion V? Diab-Deaf. 1.54 1.53 
B9 8m; M 6, epilepsy II, IV(?) 2.17 1.83 
B10 9m; F 2, 6, Mend 1 + All complexes 0.92 ! .25 
Bt l  10m; F 5 IV 1.70 0.92 
B12 10m; M 2, Mend I II 2.10 1.23 
BI3 l lm; F 2, 6, 7 + II 1.60 1.90 
B14 16m; M 2, 4, 15 + I, IV 1.53 0.50 
BI5 2; M 2, 17 + Succinate 0.90 1.00 
B16 9; M l I 2.33 2.7l 
B 17 11 ; F 11, epilepsy II, II + III 1.40 1.00 
B18 13; F 3, 16 II, IV 1.77 1.88 
BI9 19; M 1 I 2.10 1.61 
B20 21;F 3, 14 + I, IV 1.34 1.00 
B21 44; F 1, 3 I, II(?) 1.84 1.50 
B22 62; F 3, cataract, Mend I IV 1.15 0.80 
64 
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C: Muscle biopsy with neither RRF nor significant respiratory chain deficiency 
No. Age; Sex Major symptoms L /P  Diagnosis CS mtCK 
C1 4m; F 2, 5, 15 + 1.84 2.26 
C2 1 lm; M 2, 12 + CMD 2.70 1.00 
C3 4; M 2, I 1.30 0.84 
C4 12; M 1 CPT II 1.60 2.78 
C5 15; M 1 CPT II 2.66 1.31 
C6 17; F 8, 10 1.36 1.50 
C7 23; M 1, exercise hyperthermia + 1.53 2.26 
C8 25; M 1 2.13 1.54 
C9 25; M 1 2.94 2.00 
C10 28; M 1 1.90 1.84 
C11 31; M 1 MAD 2.70 2.25 
C12 33; F 3, 18 1.66 1.50 
C13 34; M 9, 10, I 1.40 1.05 
C14 35; F 3 2.10 1.93 
C15 40; F 3 2.30 1.79 
C 16 45; M Myoclonic epilepsy 1.26 2.23 
C17 47; F 3 1.50 0.91 
C18 47; M 1, sportsman + 1.74 2.65 
C19 50; F 1 1.39 0.95 
C20 52; M 9, 16 0.60 0.75 
C21 53; M 9, Mat I + 2.83 1.28 
C22 55; M 1 1.80 1.17 
C23 64; F 3 1.70 3.15 
C24 72; M 1 MAD 2.50 2.50 
Age: expressed either in years or in months (number followed by m). Major symptoms: ome major symptoms that could suggest a mitochondrial disease 
are reported: 1, exertional muscle pain; 2: hypotonia; 3: limb girdle myopathy; 4, progressive external ophthalmoplegia; 5, encephalopathy; 6, blindness; 7, 
deafness; 8, stroke-like pisodes; 9, ataxia; 10, mental retardation; 11, pigmentary retinopathy; 12, myocardiopathy; 13, diabetes mellitus; 14, kidney 
impairment; 15, liver impairment; 16, lipomatosis; 17, failure to thrive; 18, migraine; 19, neuropathy. When several patients have been identified in the 
family, the inheritance is indicated as mendelian (Mend. I), maternal (Mat. I) or unspecified (I). L /P  ratio: when indicated (+),  abnormal high 
concentrations of lactate and/or increased lactate/pyruvate ratio in blood or cerebrospinal fluid has been observed either at rest or after a meal or after a 
standardized aerobic exercise. RRF, mtDNA modifications and respiratory deficiencies were identified as described in Section 2. I, II or IV indicates a
deficiency restricted to substrates oxidized via complex I, complex II or complex IV. Complex V(?) deficiency was suggested by an inability of ADP to 
increase the rate of substrate oxidation with no apparent deficiency in uncoupled substrate oxidation rate and no apparent uncoupling. 'All complexes' 
indicates that the oxidation of all substrates was impaired. KG oxidation indicates a decreased oxidation of 2-ketoglutarate [18]. OX Phos: oxidative 
phosphorylation. Diagnosis: 'KGDH': 2-Ketoglutarate dehydrogenase d ficiency; 'Diab-Deaf.': diabetes mellitus with deafness; 'KSS': Kearns-Sayre 
syndrome; 'MELAS': mitochondrial encephalomyopathy, lactic acidosis and stroke-like pisodes; 'PEO': progressive external ophtalmoplegia; 'Leigh': 
Leigh syndrome; 'CPT II', carnitine palmityl transferase 1I deficiency; 'MAD': myoadenylate deaminase deficiency; 'CMD': congenital muscular 
dystrophy; 'IBM': inclusion bodies myositis, Cyt b * : in the biopsy of this patient which presents a new mutation on cytochrome b [29,30], all type I fibers 
looked ragged red. % RRF: % of muscle fibers exhibiting RRF. Citrate synthase (CS) and mtCK activities are expressed as /xmol acetyl coenzyme A or 
ATP transformed, min-1 . mg protein-1. 
lyzed by immunoblotting after electrophoretic separation 
of the isoforms on cellulose acetate strips (SEBIA) at 7 
mA per cellogel, at 2°C for 30 rain. The electrophoretic 
buffer contained 60 mM Barbital (Na), 10 mM Barbital, 60 
mM Tris-HC1, 15 mM EGTA and 1 mM /3-mercapto- 
ethanol (pH 8.8). Electrotransfer on nitrocellulose was 
performed in a semi-dry apparatus (Hoeffer), using 10 mM 
CAPS (3-(cyclohexylamino)-l-propanesulfonic acid), 10 
mM methanol (pH 11), as transfer buffer. The presence of 
the different isoforms was detected with a primary anti- 
creatine kinase antibody raised in guinea pig and a sec- 
ondary peroxidase-labelled anti-guinea pig antibody 
(Sigma). The primary antibody could recognize all CK 
isoforms and was used at a dilution of 1:2000 while the 
secondary antibody was diluted 1:3000. The ECL chemilu- 
minescent assay (Amersham) was used according to the 
manufacturer instructions. HeLa cells were used as the 
source of mtCK and CK-B isoforms [26]. Rabbit muscle 
M-CK was obtained from Boehringer. 
3. Results 
3.1. Mitochondrial deficiencies related to the presence or 
absence of RRF in patient muscle biopsies 
Table 1 summarizes the main clinical, histochemical 
and biochemical features in patients who have been inves- 
tigated for mitochondrial myopathy and mtCK activity. 
These patients are separated into three categories: patients 
whose muscle biopsy exhibited RRF and cytochrome oxi- 
dase negative fibers, patients with muscles which did not 
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exhibit RRF in spite of a demonstrated oxidative phospho- 
rylation defect and patients for whom neither RRF nor 
oxidative phosphorylation defect could be identified in 
muscle. It cannot be excluded that the latter category 
included either patients suffering from diseases unrelated 
to mitochondria, or patients for whom the disease was not 
sufficiently evolved to permit he identification of deficien- 
cies in the rate of functioning of oxidative phosphorylation 
components that could be significant when compared to 
controls. In each category, the patients are sorted accord- 
ing to their age. No RRF could be observed in the muscle 
biopsy of the 17 patients that were younger than 3 years, 
although oxidative phosphorylation defects could be identi- 
fied in 15 of them. One of them (B8, 7 months old) 
presented a mtDNA deletion detected only by PCR. In all 
other cases presenting a mtDNA deletion, it could be 
visualized by Southern blotting with variable levels of 
heteroplasmy [27,28]. All patient muscles but the above 
one (B8), for which a mtDNA modification (deletion or 
mutation) has been observed, exhibited RRF. 
RRF were present not only in patient muscle biopsies 
exhibiting oxidative phosphorylation defects but also in 
one patient with a Krebs cycle deficiency (2-ketoglutarate 
dehydrogenase d ficiency). However, the presence of RRF 
was not systematically correlated to other mitochondrial 
enzyme deficiencies of nuclear origin. Indeed, several 
patients with complex II or carnitine palmitoyl transferase 
II deficiency, for example, did not exhibit RRF in their 
muscle biopsy (see Table 1B,C). In addition, 3 patients 
(Cases A12, A17 and A22) for whom no apparent impair- 
ment in either substrate oxidation or respiratory chain 
complex activity was identified, nevertheless presented 
RRF in their muscle. One of those (A22) was 64 years old, 
suffered from painful limb girdle myopathy, had increased 
L /P  ratio and prolonged recovery after exercise of the 
inorganic phosphate/phosphocreatine ratio, as shown by 
31p nuclear magnetic resonance spectroscopy. These data 
could be related to an unknown deficiency in energy 
metabolism. For the two other patients without identified 
substrate oxidation or respiratory chain complex defect 
who exhibited RRF (Cases A12 and A17), L /P  also were 
normal. However, for these two patients, the mitochondrial 
creatine kinase activity was among the highest ones mea- 
sured in the mitochondria isolated from the 69 analyzed 
patients. 
Attempts to detect paracrystalline inclusions in the 
mitochondrial pellets of the two MELAS patients (A6; A7) 
and one PEt  patient (A14) exhibiting both RRF and high 
creatine kinase activities were unsuccessful. 
3.2. Validity o f  mtCK measurements 
Several controls were performed to assess that the CK 
activity measured on isolated mitochondria were valid. 
Since all CK isoforms have the same size, SDS-PAGE and 
Western blotting were not useful in their identification, but 
the various CK isoforms could be separated by elec- 
trophoresis on cellulose acetate strips and a transfer tech- 
nique was devised to set up a sensitive immunoassay. Fig. 
1 shows that no contaminating cytosolic CK could be 
detected in purified mitochondria, using this sensitive im- 
munoassay after separation of the various CK isoforms by 
electrophoresis on cellulose acetate strips: in Fig. 1A, the 
samples have been spotted in the middle of the cellulose 
acetate strip. The B-CK migrates towards the anode, the 
M-CK barely migrates from the origin towards the cath- 
ode, and the two mtCK forms (octamer and dimer) migrate 
further away towards the cathode, as previously described 
[31]. However, it was difficult to ascertain that no M-CK 
was present in the isolated mitochondria since some de- 
posited material remained at the origin, close to the M-CK 
position. An improved separation between the origin, the 
M-CK and the mtCK isoforms was obtained by spotting 
the samples near the cathode (Fig. 2B) and running the 
mt( 
Mitoch HeLa cells M-CK 
n 
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imer I ,l=t~f,, 
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® 
Fig. 1. Immunodetection of the creatine kinase isoforms present inisolated mitochondria. Hela cells: 100 /~g of proteins. The frozen cells were suspended 
in 10 mM Tris-HCl, 0.2 mM dithiothreitol (pH 7.5), maintained in an ice-bucket and sonicated 6 times for 5 s separated by3 s of cooling with a Branson 
sonifier, equipped with a 0A-cm diameter p obe. Mitoch: 1 /zg of mitochondrial proteins suspended in the same buffer as the Hela cells; M-CK: 0.15 /xg 
of rabbit muscle creatine kinase. Electrophoresis on cellulose acetate strips, transfer to nitrocellulose membranes and immunodetection were performed as
described inSection 2. Left (A): samples spotted on the center of the cellulose strip. Right (B): samples spotted near the cathode. 
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Fig. 2. Lack of correlation between mitochondrial creatine kinase activity 
and activation of citrate synthase (CS) by Triton X-100. The citrate 
synthase activity was measured in the mitochondria before and after 
addition of 0.1% Triton X-100. The ratio between these two measure- 
ments (CS + Triton/CS-Triton) is plotted as a function of the creatine 
kinase activity measured in the same mitochondrial sample. Creatine 
kinase is expressed as mU of substrate transformed per min and per mg 
of protein. 
electrophoresis for a short time. Under these conditions, all 
isoforms migrate towards the anode, the M-CK migrating 
in front of the mtCK. This clear separation of the different 
CK isoforms demonstrates that the isolated mitochondria 
do not contain detectable amounts of M-CK. This control 
has been repeated for several muscle biopsies, particularly 
for those exhibiting the lowest or highest mtCK activities. 
The presence of M-CK could never be visualized with the 
antibody. 
Another possible cause of error could be a loss of mtCK 
during mitochondrial isolation due to damage of the mito- 
chondrial membranes. In such a case, a low creatine kinase 
activity should be associated to damaged mitochondrial 
membranes. The integrity of the mitochondrial membrane 
was assessed by the effect of Triton X-100 on the citrate 
synthase activity. When mitochondrial membranes are 
damaged, the citrate synthase substrates are accessible to 
the citrate synthase located inside the matrix. On the 
contrary, in intact mitochondria, the addition of a detergent 
such as Triton X-100 is necessary to make the substrates 
accessible to the enzyme and unveil the activity. The ratio 
between the citrate synthase activity in the presence or 
absence of detergent is therefore an index of the percent- 
age of intact mitochondrial membranes, the highest ratios 
being correlated with the best integrity. Fig. 2 shows that 
the lowest creatine kinase activities were not correlated 
with low ratios and conversely, high creatine kinase activi- 
ties were not associated with high ratios. 
3.3. Correlation between presence of RRF or oxidative 
phosphorylation defects with rntCK or citrate synthase 
activities 
The mtCK and citrate synthase activities measured in 
the mitochondria isolated from each muscle biopsy are 
reported in Table 1A-C. Absence of mtCK activity was 
never observed and the lowest activities (0.5 units per mg 
of mitochondrial protein) were not specifically associated 
with defects of respiratory chain complexes or with defects 
of tricarboxylic acid cycle enzymes. In one patient, it was 
associated with a disease that was diagnosed as a congeni- 
tal muscular dystrophy (B7); in another patient (B14), it 
was associated to an undefined multisystemic disorder. 
Table 2 shows that there is a significant increase in 
mtCK activity in muscles with RRF when compared to 
muscles without RRF either with or without a respiratory 
chain defect. On the contrary, in biopsies which are devoid 
of RRF, there is no significant difference between mito- 
chondrial creatine kinase activities whether or not a respi- 
ratory chain defect could be detected. Although mtCK and 
citrate synthase activities are significantly higher in the 
group of patients exhibiting RRF than in the other two 
groups, there is some overlap between individual results: 7 
(A4, A10, A l l ,  A13, A15, A22, A23) out of the 23 
patients with RRF (Table 1A) have a mtCK activity lower 
than the average observed for the patients without RRF 
(Table 2); 2 (B4 and B16) out of the 22 patients in the 
second group (Table 1B) and 4 (C4, C18, C23 and C24) 
out of 24 patients of the third group (Table 1C) exhibited 
mtCK activities higher than the average observed for RRF 
patients (Table 2) and 4 others (C1, C7, C l l  and C16) had 
mtCK activities close to this average. In addition, no direct 
correlation could be made between the percentage of RRF 
estimated in muscle slices and mtCK activity measured in 
Table 2 
Increase of creatine kinase and citrate synthase activities in mitochondria solated from the muscle biopsy of patients exhibiting RRF 
Patients n Creatine kinase mU/min  Citrate synthase/~mol/min 
per mg protein per mg protein 
With RRF (A) 
Resp. chain deficiency, no RRF (B) 
No resp. chain deficiency, no RRF (C) 
(A) versus (B) 
(A) versus (C) 




2.29 _+ 1.02 2.31 _+ 0.77 
1.41 + 0.65 1.69 +_ 0.40 
1.67 +_ 0.65 1.89 + 0.60 
Significance between categories 
P < 0.001 P < 0.002 
P < 0.02 P < 0.05 
N.S. N.S. 
Data obtained from Table 1 are presented as a mean ___ standard eviation, n, number of patients. The significance (P)  of the differences between the three 
patient categories has been calculated by a t-test. N.S., not significant. 
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Fig. 3. Correlation between mitochondrial creatine kinase and citrate 
synthase activities. Creatine kinase and citrate synthase are expressed 
respectively as mU and /zmol of substrate transformed per rain and per 
mg of protein. Filled squares: muscle biopsies with RRF; empty squares: 
muscle biopsies without RRF and with oxidative phosphorylation defi- 
ciencies; empty circles: muscle biopsies without RRF and without oxida- 
tive phosphorylation deficiency. 
isolated mitochondria. Therefore, appearance of RRF and 
mtCK increase seem to generally occur simultaneously but 
other factors must be involved that can interfere with one 
or the other event. 
Table 2 also shows that, not only mtCK activity was 
increased in mitochondria solated from muscles exhibiting 
RRF, but also citrate synthase activity was increased. Fig. 
3 shows that the correlation between mtCK and citrate 
synthase is observed in most individual patients. However, 
a few patients presented a low mtCK with a high citrate 
synthase activity. On the contrary, when mtCK was high, 
citrate synthase was always high. 
In this study, the patients presenting respiratory defi- 
ciency without RRF were younger than those exhibiting 
RRF and, except for one case (B4), those younger than 3 
years never exhibited them. This could introduce an age- 
related bias in the analysis. Attempts to correlate mito- 
chondrial creatine kinase activity or citrate synthase activ- 
ity with age in the studied population was unsuccessful 
when the patients were considered either all together or 
according to the categories defined in Table 1A,B,C. 
4. Discussion 
4.1. Technical problems in testing the mtCK activity in 
mitochondrial diseases. 
To our knowledge, rare studies have been performed 
previously about mtCK activity in mitochondrial diseases 
[17]. This may be due in part to the difficulty encountered 
for the specific determination f this activity. Indeed, large 
amounts of the cytoplasmic creatine kinase isoenzyme are 
present in the muscle fiber and variable amounts of M-CK, 
MB-CK and eventually B-CK isoforms might be found in 
patients, especially during perinatal development. This can 
interfere with the determination of the mtCK activity. 
Smeitink et al. [32] have solved this problem by using a 
sophisticated technique including removal from muscle 
homogenate of B-CK by treatment with DEAE-cellulose 
and of M-CK by immunoadsorption to a M-CK specific 
antibody. Therefore, this method measures non-B-CK and 
non-M-CK activity in normal muscle. However, it has 
been reported that tissues that normally do not contain 
B-CK are able to express this isoform under developmen- 
tal or pathological circumstances [33]. In this case, there 
might be a risk of overestimation of mtCK due to the 
contribution of MB and BB isoforms, if these activities are 
too high to be completely removed by pretreatment with 
DEAE-cellulose. However, this is the only usable tech- 
nique in muscle homogenates from small size or from 
frozen biopsies, when mitochondria cannot be purified. 
Previous studies [31] have shown that mtCK remains 
associated to the mitochondria provided that both the 
mitochondria isolation medium was iso-osmotic and ade- 
nine nucleotides, high salt concentrations, or high pH were 
not present in the medium. Hence, the CK activity associ- 
ated with purified mitochondria prepared under these con- 
ditions should give a good estimation of the activity 
present in situ, unless mitochondria were contaminated by 
cytosolic reatine kinase. The data presented here demon- 
strate that, after separation of mtCK and cytosolic CK by 
electrophoresis, neither M-CK nor B-CK nor MB-CK, 
important to study especially in young children, could be 
detected in the mitochondrial fraction by immunostaining 
using a sensitive chemiluminescent assay. This test was 
performed with several patients exhibiting high, medium, 
or low CK activity. Since this assay was more sensitive 
than the activity assay used in this study, it can be 
concluded that cytosolic CK could not significantly con- 
tribute to the activity measured in purified muscle mito- 
chondria. 
Another source of incorrect estimation of the mtCK 
activity might be due to a loss of mtCK during mitochon- 
drial preparation linked to a damage of the mitochondrial 
membranes. Citrate synthase is located inside the matrix. 
In the absence of detergent, his activity was low because 
the substrate, acetyl-coenzyme A, was not freely accessible 
to the enzyme when the mitochondrial membranes were 
intact. The addition of detergent increased the rate of 
coenzyme A production. The ratio between the citrate 
synthase activity in the presence and the absence of deter- 
gent is therefore a measure of the integrity of the mito- 
chondrial membranes. If the mitochondrial membranes 
were damaged and that mtCK was leaking out of the 
mitochondria during the preparation, low mtCK activities 
should be correlated to low activation of citrate synthase 
activity by Triton X-100. The lack of correlation between 
mtCK activity and detergent-induced activation of citrate 
synthase rules out this type of error. In conclusion, mtCK 
activity can be easily measured provided that well-coupled 
mitochondria can be prepared from the muscle biopsy. 
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In previous studies, crystal-like paracrystalline inclu- 
sions heavily reacting with specific anti-mtCK antibodies 
have been observed in muscle biopsies containing RRF 
[13-15]. In our studies, no crystal-like structures have 
been observed in the mitochondrial pellets which have 
been analyzed by electron microscopy, although these 
pellets were obtained from adult patient muscles exhibiting 
numerous RRF and a few paracrystalline inclusions. It is 
quite possible that these inclusions could be lost during the 
isolation procedure. Indeed, the average yield during the 
mitochondrial isolation procedure was around 30-40%, as 
reported by other authors [34]. It cannot be excluded that 
the yield of mitochondria containing these paracrystalline 
inclusions could be lower than the average yield. In this 
case, the increase in mtCK activity observed in this study 
for muscles containing RRF might be underestimated in 
the case of patient muscles containing paracrystalline in- 
clusions, since the latter are known to be rich in mtCK 
[13-15]. 
4.2. Lack of  mtCK in mitochondrial diseases? 
In several instances, in our study as well as in other 
reports [17,35], the rate of substrate oxidation and/or of 
ATP production by the mitochondria were diminished 
while no significant decrease in the activity of either the 
dehydrogenases or the respiratory chain complexes could 
be identified. Smeitink et al. [17,35] suggested that a low 
mtCK activity could be one of the causes of the impaired 
energy metabolism. None of our patients exhibited a com- 
plete loss of mtCK activity. The lowest mtCK activities 
(0.5 mU) observed for one patient suffering from a con- 
genital muscular dystrophy (B7) and for one patient with 
an unknown disease (B14) were both associated to de- 
creased respiratory chain complex activities and, hence, 
did not correspond to specific mtCK deficiency. This study 
failed to demonstrate a mtCK deficiency as the primary 
event in patients with a disturbance of mitochondrial en- 
ergy production. It further substantiates that of Smeitink et 
al. [17,35], indicating that it must be very rare, if it exists. 
4.3. RRF and mitochondrial diseases 
In mitochondrial diseases, the variability of the clinical 
presentation, of the eventual biochemical defects and the 
frequent lack of knowledge about the mitochondrial or 
nuclear DNA modifications that could induce these dis- 
eases make their characterization difficult. Although the 
diagnostic importance of histochemical studies of muscle 
biopsies is well established, a small number of RRF and 
COX-negative fibers are occasionally observed in the el- 
derly, in other muscle diseases, such as muscular dystro- 
phy or glycogen storage diseases [36,37], and under vari- 
ous pathological conditions uch as ischemia [38] or after 
AZT therapy [39]. Our study confirms that RRF can be 
observed in diseases for which a nuclear gene is involved: 
for example, in case A1, there is a deficiency in 2-keto- 
glutarate dehydrogenase. In other cases with RRF, no 
specific mitochondrial dehydrogenase or respiratory chain 
defect has been identified until now (cases AI2, A17, A21, 
A22), but it cannot be excluded that these muscles are 
deficient for enzymes important in mitochondrial energy 
metabolism which have not been tested in this study. 
Conversely, muscle biopsies with an oxidative phospho- 
rylation deficiency do not always exhibit RRF (Table 1B). 
In addition, our study put forward the fact that RRF are 
very rare in babies and young children. 
4.4. Variation of  creatine kinase activity with age 
Sped et al. [40] have shown that pyruvate oxidation 
rate, citrate synthase and NADH-ubiquinone oxidoreduc- 
tase in skeletal muscle were lower in preterm and fullterm 
neonates than that of controls of more than 5 years. 
Smeitink et al. [32] also demonstrated a clear prenatal 
increase for mtCK of human skeletal muscle. In rat, vari- 
ous enzymes involved in the energy production increased 
up to the weaning period. To our knowledge, no data 
demonstrated any difference in mtCK activity within the 
age range that we have studied (3 months to 72 years). 
Attempts to correlate the mtCK activity changes either in 
all patients or in one of our classes of patients were 
unsuccessful. It is therefore very likely that the variability 
of the mtCK activity may rather be related to metabolic 
control than depending upon the patient age, at least in this 
age range. In addition, our study of citrate synthase activ- 
ity extends that of Lefai et al. [41] who have shown that 
this activity did not significantly vary over ages ranging 
between 3 and 19 years. 
4.5. Correlation between mtCK activity increase and pres- 
ence of  RRF 
The data presented here demonstrate a statistically sig- 
nificant increase of about 50% in the mtCK activity of 
isolated mitochondria, when comparing the muscles of 
patients with or without RRF. The presence of mtCK in 
RRF was previously demonstrated by immuno-electro- 
nmicroscopy [13-15], suggesting that mtCK represents a 
major component of mitochondrial crystal-like inclusions. 
However, an increase of mtCK activity in muscle ho- 
mogenates was only observed in muscle samples of 2 PEt  
patients in which mitochondrial crystals were present [16]. 
Four other PEt  patient muscles had a normal mtCK 
activity. Similarly, in our study, some patients for which 
RRF had been observed (group A) did not exhibit in- 
creased CK activity in their mitochondria. Besides, two 
patients A12 and AI7, exhibiting levels of mtCK activities 
among the highest ones, had no identified oxidative phos- 
phorylation defect. However, as mentioned above, it can- 
not be excluded that an enzyme involved in mitochondrial 
energy metabolism, not yet identified in this study, could 
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be deficient for these patients. In addition, a few patients 
devoid of RRF had an increased mtCK activity. This is the 
case for patients B4 and B16 which are young patients 
with a complex I defect, for patient C4 with a carnitine 
palmitoyl transferase II deficiency; for patients C l l  and 
C24 with a myoadenylate deaminase deficiency and for 
patient C18 who had been a highly performing sportsman 
and exhibited elevated serum lactate to pyruvate ratios. 
However, these specific deficiencies were not always asso- 
ciated with an increased mtCK activity. In conclusion, in 
spite of the overlap observed between the groups of stud- 
ied patients, an increased mtCK activity is generally asso- 
ciated with RRF. In muscles without RRF, an increased 
mtCK activity is very likely indicative of a mitochondrial 
deficiency, even when this defect has not been yet charac- 
terized by biochemical or genetic techniques. This conclu- 
sion also applies to citrate synthase activity which was also 
generally increased in muscle samples containing RRF, as 
previously observed by others [17,32]. Overexpression f
mtCK together with the B-CK isoform has also been 
reported in various solid tumors and tumor cell lines. 
However, in these cases, this is the ubiquitous isoform of 
mtCK which is present [33]. 
MtCK activity was lower in the absence than in the 
presence of RRF, even when a mitochondrial deficiency 
was clearly demonstrated (Table 2B). However, all but 3 
patients without RRF and with oxidative phosphorylation 
deficiency were younger than 20 years old, while all but 5 
patients with RRF were older than 20 years old. This 
suggests that mtCK activity as well as the presence of RRF 
increase with age in mitochondrial diseases and that an 
mtCK increase may appear later in life than oxidative 
phosphorylation deficiency. MtCK increase and RRF ap- 
pearance are therefore very likely long-term secondary 
processes which slowly develop in mitochondria deficient 
towards oxidative phosphorylations. However, since no 
direct correlation could be made between the amount of 
RRF and mtCK activity, other independent factors should 
interfere with either RRF formation or mtCK activity 
increase. The precise mechanisms which determine these 
events remain unknown. RRF formation is certainly related 
to a general up-regulation of mitochondrial protein synthe- 
sis, as shown in histochemistry and electron microscopy by 
mitochondrial proliferation at the periphery of the fibers. 
In addition, the increase in citrate synthase and mtCK 
activities calculated per mg of protein in isolated mito- 
chondria, reveals a specific induction of these proteins, as 
compared to other mitochondrial proteins. Further work is 
necessary to understand these inductions. 
4.6. Increase of mtCK and of adenine nucleotide transloca- 
tor in RRF 
Several groups have demonstrated that mtCK is func- 
tionally coupled to the mitochondrial denine nucleotide 
translocator [42-44]. It is very likely that the mtCK syn- 
thesis induction observed in RRF is accompanied by an 
increased synthesis of adenine nucleotide translocator. In- 
deed, a 3-fold increase in the steady-state amounts of 
mRNAs coding for adenine nucleotide translocator and for 
mitochondrial ATPase /3 subunit has been observed in the 
muscle homogenate of a MERRF patient [45]. An increase 
in the ATPase fl subunit ranscript was also observed by 
in situ hybridization i the RRF of several patients present- 
ing mtDNA deletions [28]. On the contrary, no significant 
accumulation of mtCK mRNAs could be detected in the 
same muscle slices, which probably means that mtCK 
mRNAs are used up faster than they are synthesized, while 
the ATPase /3 subunit and the adenine nucleotide translo- 
cator mRNAs can accumulate. It will be interesting to 
check whether an adenine nucleotide translocator accumu- 
lation occurs in RRF in parallel to mtCK accumulation, 
when a histological technique will be available to visualize 
the adenine nucleotide translocator. 
Acknowledgements 
This work was supported by grants from the 'Associa- 
tion Fran~aise contre les Myopathies', the 'REgion 
Rhtne-Alpes', the French CNRS and the 'Universit6 
Claude Bernard de LYON I'. The authors acknowledge P.
Guibaud (MD) and N. Guffon (MD) for referring the 
children cases, B. Bady (MD) and F. Flocard (MD) for 
referring the adult cases. The authors would also like to 
thank G. Baverel (PhD), J.M. Collombet (PhD), R. Du- 
moulin (PhD), I. Maire (PhD), B. Mousson (PhD), M.T. 
Zabot (PhD) for their expertise in the laboratory investiga- 
tions of these patients. M.F.B., C.L-M. and N.E. were 
supported by the Moroccan government, he foundation 
Ramon Areces (Spain) and the 'Association Fran~aise 
contre les Myopathies', respectively. 
References 
[1] Wallace, D.C., Lott, M.T., Brown, M.D., Huoponen, K. and Torroni, 
A. (1995) Report of the committee on human mitochondrial DNA. 
in Cutichia, A.J. (Ed.), Human Gene Mapping 1995: A Com- 
pendium. John Hopkins University Press, Baltimore, pp 910-954. 
[2] Holt, l.J., Harding, A. and Morgan-Hughes, J.A. (1988) Nature 331, 
717-719. 
[3] Zeviani, M., Moraes, C.T., Di Mauro, S., Nakase, H., Bonilla, E., 
Schon, E. and Rowland, L.P. (1988) Neurology 38, 1339-1346. 
[4] RiStig, A., Colonna, M., Blanche, S., Fischer, A., Le Deist, F., 
Frezal, J., Saudubray, J.M. and Munnich, A. (1989) Lancet l, 
902-903. 
[5] Ballinger, S.W., Shoffner, J.M., Hedaya, E.V., Trounce, I., Polak, 
M.A., Koontz, D.A. and Wallace, D.C. (1992) Nature Genet. 1, 
11-15. 
[6] Anderson, S., Banquier, A.T., Barrel, B.G., De Bruijn, M.H.U, 
Coulson, A.R., Drouin, J., Eperon, I.C., Nierlich, D.P., Rose, B.A., 
Sanger, F., Schreier, P.H., Smith, A.J.H., Staden, R. and Young, 
I.G. (1981) Nature 290, 457-465. 
[7] Goto, Y., Nonaka, I. and Horai, S. (1990) Nature 348, 651-653. 
70 M.F. Bouzidi et al. / Biochimica et Biophysica Acta 1316 (1996) 61-70 
[8] Shoffner, J.M., Lott, M.T., Lezza, A.M., Seibel, P., Ballinger, S.W. 
and Wallace, D.C. (1990) Cell 61,931-937. 
[9] Stadhouders, A.M. (1981) in Mitochondria nd Muscular Diseases 
(H.F.M. Busch, F.G.I. Jennenkens and H.R. Scholte, Eds.), pp. 
113-132, Mefar h.v. Beetsterzwaag, The Netherlands. 
[10] Engel, W.K. and Cunningham, G.C. (1963) Neurology 13, 919 
-923. 
[11] Shoubridge, E.A., Karpati, G. and Hastings, K.E.M. (1990) Cell 62, 
43 -49. 
[12] Farrants, G., Hovmtiller, S. and Stadhouders, A.M. (1988) Muscle 
Nerve 11, 45-55. 
[13] Stadhouders, A.M., Jap, J. and Walliman, T. (1990) J. Neurol. Sci. 
98 (Suppl.) 304-305. 
[14] Stadhouders, A.M., Jap, J., WinNer, H.P. and Walliman, T. (1992) 
J. Muscle Res. Cell Motil. 13, 255A. 
[15] Stadhouders, A.M., Jap, P.H.K., Winkler, H.P., Eppenberger, H.M. 
and Wallimann, T. (1994) Proc. Natl. Acad. Sci. USA 91, 5089- 
5093. 
[16] Smeitink, J., Stadhouders, A.M., Sengers, R.C.A., Ruitenbeek, W., 
Wevers, R., Ter Laak, H. and Trijbels, J.M.F. (1992) Neuromusc. 
Disord. 2, 35-40. 
[17] Smeitink, J., Ruitenbeek, W., Sengers, R., Wevers, R., Lith, T.v. and 
Trijbels, F. (1994) J. Inher. Metab. Dis. 17, 67-73. 
[18] Guffon, N., Lopez-Mediavilla, C., Dumoulin, R., Mousson, B., 
Godinot, C., Carrier, H., Collombet, J.M., Divry, P., Mathieu, M. 
and Guibaud, P. (1993) J. Inherit. Metab. Dis. 16, 821-830. 
[19] Robinson, B.H. (1989) in The Metabolic Basis of Inherited Diseases, 
6th edition (Scriver, C.R., Beaudet, A.L., Sly, W.S. and Valle, D., 
Eds.), pp. 869-888, McGraw-Hill, New York. 
[20] Seligman, A.M., Kamovsky, M., Wasserknlg, H. and Hanker, J. 
(1968) J. Cell. Biol. 38, 1-14. 
[21] Watterburg, L.W. and Leong, J.L.(1960) J. Histochem. Cytochem. 8, 
296-300. 
[22] Bouzidi, M.F., Sch~igger, H., Collombet, J.M., Carder, H., Flocard, 
F., Quard, S., Mousson, B. and Godinot, C (1993) Neuromusc. 
Disord. 3, 599-604. 
[23] Srere, P. (1989) Methods Enzymol. 13, 3-11. 
[24] Lang, R.D.A. (1987) in Mitochondria, apractical approach (Darley- 
Usmar, V.M., Rickwood, D. and Wilson, M.T., Eds.), pp. 17-19, 
IRL press, Oxford. 
[25] Font, B., Vial, C., Goldschmidt, D., Eichenberger, D. and Gau- 
theron, D.C. (1983) Arch. Biochem. Biophys. 220, 541-548. 
[26] Van Brussel, E., Yang, J.J., and Seraydarian, M.W. (1983) J. Cell 
Physiol. 116, 221- 226. 
[27] Dumoulin, R., Mandon, G., Collombet J.M., Carrier, H,. Godinot C., 
Flocard, F., Villard, J., Guibaud, P., Mathieu, M. and Mousson, B. 
(1993) J. Inherit. Metab. Dis. 16, 545-547. 
[28] Carder, H., Burt-Pichat, B., Flocard, F., Mousson, B., Dumoulin, R., 
Guffon, N. and Godinot, C. (1996) Acta Neuropathol. 91, 112-116. 
[29] Bouzidi, M.F., Carrier, H. and Godinot, C. (1995) EUROMIT 1II: 
3rd International Meeting on Human Mitochondrial Pathology 
(Chantilly, France), Abstract book, p. 116. 
[30] Dumoulin, R., Saignol, I., Ferlin, T., Stepien, G. and Mousson, B. 
(1995) EUROMIT III: 3rd International Meeting on Human Mito- 
chondrial Pathology, (Chantilly, France), Abstract book, p. 78. 
[31] Vial, C., Marcillat, O., Goldschmidt, D., Font, B. and Eichenberger, 
D. (1986) Arch. Biochem. Biophys. 251,558-566. 
[32] Smeitink, J., Ruitenbeek, W., Lith, T.v., Sengers, R., Trijbels, F., 
Wevers, R., Sped, W. and De Graaf, R. (1992) Anal. Clin. Biochem. 
29, 302-306. 
[33] Walliman, T. and Hemmer, W. (1994) Mol. Cell. Biochem. 133-134, 
193-220. 
[34] Rustin, P., Chretien, D., Bourgeron, T., G6rard, B., RiStig A., 
Sandubray, J.M. and Munnich, A. (1994) Clin. Chim. Acta 228, 
35-51. 
[35] Smeitink J., Wevers, R., Hulshof, J., Ruitenbeek, W., Lith, T.v., 
Sengers, R., Trijbels, F., Korenke, C. and Walliman, T. (1992) Ann. 
Clin. Biochem. 29, 196-201. 
[36] Mtiller-HiScker, J. (1990) J. Neurol. Sci. 100, 14-21. 
[37] Yamamoto, M, Koga, Y, Ohtaki, E. and Nonaka, I. (1989) J. Neurol. 
Sci. 91,207-213. 
[38] Hanslikova, V. and Schiaffino, S. (1977) J. Ultrastructure Res. 60, 
121-133. 
[39] Dalakas, M.C., Illa, I., Pezeshkpour, G.H., Laukaitis, J.P., Cohen, B. 
and Griffin, J.N. (1990) N. Engl. J. Med. 322, 1098- 1105. 
[40] Sped, W., Sengers, R.C.A., Trijbels, J.M.F., Ruitenbeek, W., Does- 
burg, W.H., Smeitink, J.A.M., Koll6e, L.A.A. and Boon, J.M. 
(1992) Ann. Clin. Biochem. 29, 638-645. 
[41] Lefai, E., Terrier-Cayre, A., Vincent, A., Boespflug-Tanguy, O., 
Tanguy, A. and Alziari, S. (1995) Biochim. Biophys. Acta 1228, 
43-50. 
[42] Moreadith, R.W. and Jacobus, W.E. (1982) J. Biol. Chem. 257, 
899-905. 
[43] Barbour, R.L., Sotak, C.H., Levy, G.C. and Chan, S.H.P. (1984) 
Biochemistry 23, 6053-6062. 
[44] Saks, V.A., Kuznetzov, A.V., Kupriyanov, V.V., Micelli, M.V. and 
Jacobus, W.E. (1985) J. Biol. Chem. 260, 7757-7564. 
[45] Heddi, A., Lestienne, P., Wallace, D.C. and Stepien, G. (1993) J. 
Biol. Chem. 268, 12156-12163. 
